JP2010516761A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516761A5
JP2010516761A5 JP2009547189A JP2009547189A JP2010516761A5 JP 2010516761 A5 JP2010516761 A5 JP 2010516761A5 JP 2009547189 A JP2009547189 A JP 2009547189A JP 2009547189 A JP2009547189 A JP 2009547189A JP 2010516761 A5 JP2010516761 A5 JP 2010516761A5
Authority
JP
Japan
Prior art keywords
combinations
composition
composition according
pyrrolidone
polyol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009547189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516761A (ja
Filing date
Publication date
Priority claimed from NZ552816A external-priority patent/NZ552816A/en
Application filed filed Critical
Publication of JP2010516761A publication Critical patent/JP2010516761A/ja
Publication of JP2010516761A5 publication Critical patent/JP2010516761A5/ja
Pending legal-status Critical Current

Links

JP2009547189A 2007-01-24 2008-01-22 局所処方物 Pending JP2010516761A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ552816A NZ552816A (en) 2007-01-24 2007-01-24 Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
PCT/NZ2008/000011 WO2008091167A1 (en) 2007-01-24 2008-01-22 Topical formulation

Publications (2)

Publication Number Publication Date
JP2010516761A JP2010516761A (ja) 2010-05-20
JP2010516761A5 true JP2010516761A5 (cg-RX-API-DMAC7.html) 2011-02-10

Family

ID=39644688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009547189A Pending JP2010516761A (ja) 2007-01-24 2008-01-22 局所処方物

Country Status (7)

Country Link
US (1) US8748467B2 (cg-RX-API-DMAC7.html)
EP (1) EP2124938A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010516761A (cg-RX-API-DMAC7.html)
AU (1) AU2008208151B2 (cg-RX-API-DMAC7.html)
CA (1) CA2713199C (cg-RX-API-DMAC7.html)
NZ (1) NZ552816A (cg-RX-API-DMAC7.html)
WO (1) WO2008091167A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
WO2012043701A1 (ja) * 2010-09-30 2012-04-05 富山化学工業株式会社 経皮吸収製剤
CN114903848A (zh) * 2013-02-27 2022-08-16 阿根塔创新有限公司 透皮制剂
EP3142641B1 (de) 2014-05-13 2020-11-25 DendroPharm GmbH Formulierungen zur behandlung von hyperthyreose
WO2016198472A1 (en) 2015-06-09 2016-12-15 Hpf Ip Holding S.A. Topical delivery system
KR20190138683A (ko) * 2017-04-21 2019-12-13 스티븐 호프만 망막병증을 치료하기 위한 조성물 및 방법
JP2024539703A (ja) * 2021-10-28 2024-10-29 ブリストル-マイヤーズ スクイブ カンパニー デュークラバシチニブの局所製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296222A (en) 1989-02-23 1994-03-22 University Of Utah Percutaneous drug delivery system
US5091182A (en) * 1990-07-23 1992-02-25 Syntex (U.S.A.) Inc. Dispensing units for ketorolac topical gel formlations
WO1994028897A2 (en) 1993-06-07 1994-12-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
CN1046089C (zh) * 1993-07-24 1999-11-03 陈凌 外敷用抗甲状腺乳膏
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
IL127189A0 (en) * 1996-05-22 1999-09-22 Diversified Pharmaceuticals In Compositions methods and devices for the transdermal delivery of drugs
WO1998003641A1 (en) * 1996-07-23 1998-01-29 Crandall Wilson T Transdermal transport of molecules
US5919436A (en) * 1997-09-25 1999-07-06 The Board Of Regents Of The University Of Oklahoma Method of lightening skin
AU3470600A (en) 1999-01-14 2000-08-01 David Houze Compositions and methods for drug delivery
US20030170195A1 (en) 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
ATE290856T1 (de) * 1999-12-16 2005-04-15 Dermatrends Inc Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
JP3962684B2 (ja) * 2000-11-06 2007-08-22 サムヤン コーポレイション 改善された水分吸収能および接着性を有する経皮投与剤
JP2007516230A (ja) * 2003-05-19 2007-06-21 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 心臓組織の変性を治療及び予防するための組成物及び方法並びにその用途
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
US20050209295A1 (en) 2004-03-16 2005-09-22 Kohn Leonard D Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
FR2873883B1 (fr) * 2004-07-28 2006-09-29 Sagem Procede de tramage d'une image
CN100406063C (zh) 2005-05-18 2008-07-30 陈凌 外敷用抗甲状腺软膏及其制备方法
CA2617934A1 (en) 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof

Similar Documents

Publication Publication Date Title
JP2008533007A5 (cg-RX-API-DMAC7.html)
JP2011506330A5 (cg-RX-API-DMAC7.html)
JP2015511638A5 (cg-RX-API-DMAC7.html)
JP5542053B2 (ja) ピルフェニドンを含有するゲル
EA032938B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
JP2016535795A5 (cg-RX-API-DMAC7.html)
RU2010139285A (ru) Производные пиридазина и их применение в качестве терапевтических агентов для лечения кожных нарушений
JP2014507455A5 (cg-RX-API-DMAC7.html)
NO20081325L (no) Nye doseringsformuleringer
RU2020110783A (ru) Полутвердая композиция для наружного применения, содержащая антимикробный агент и пирфенидон для лечения хронического повреждения кожи
JP2010513500A5 (cg-RX-API-DMAC7.html)
WO2008082507A3 (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
JP2015516496A5 (cg-RX-API-DMAC7.html)
JP2011219364A (ja) 経皮吸収促進剤、および該経皮吸収促進剤を含有する経皮製剤
JP2010526827A5 (cg-RX-API-DMAC7.html)
WO2015038552A3 (en) Aspirin formulation for increased efficacy
CN1227005C (zh) 含尼美舒利的局部药用组合物
JP2011507904A5 (cg-RX-API-DMAC7.html)
WO2010020799A3 (en) Compositions for the treatment of neoplastic diseases
CA2474246A1 (en) Alkylammonium salts of omeprazole and esomeprazole
JP2006523723A5 (cg-RX-API-DMAC7.html)
JP2008532967A5 (cg-RX-API-DMAC7.html)
RU2015129081A (ru) Гелевые композиции
CN101917973B (zh) 从药物组合物中回收氟尼辛的方法
JP2007504222A5 (cg-RX-API-DMAC7.html)